STEVEN FOUNG, M.D.
Medical Practice at Hillview Ave, Palo Alto, CA
License number
California G32807
Category
Medical Practice
Type
Pediatrics
Address
Address
3373 Hillview Ave, Palo Alto, CA 94304
Phone
(650) 723-6481
(650) 725-6610 (Fax)
(650) 725-6610 (Fax)
Organization information
See more information about STEVEN FOUNG at bizstanding.comStanfordresearch Laboratory - Steven Foung MD
800 Welch Rd #221, Palo Alto, CA 94304
Categories:
Pediatrics Physicians & Surgeons
Phone:
(650) 723-6481 (Phone)
Professional information
Steven Kh Foung, Palo Alto CA
Specialties:
Pathology, Blood Banking & Transfusion Medicine, Anatomic Pathology & Clinical Pathology, Clinical Pathology/Laboratory Medicine, Pediatrics
Work:
Stanford Blood Center
3373 Hillview Ave, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
3373 Hillview Ave, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
Education:
University of California at San Diego (1975)
Dr. Steven Foung, Palo Alto CA - MD (Doctor of Medicine)
Address:
Stanford Blood Center
3373 Hillview Ave, Palo Alto 94304
(650) 723-2597 (Phone)
3373 Hillview Ave, Palo Alto 94304
(650) 723-2597 (Phone)
Hospitals:
Stanford Blood Center
3373 Hillview Ave, Palo Alto 94304
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
3373 Hillview Ave, Palo Alto 94304
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical Schools
University of California At San Diego
Graduated: 1975
University of California At San Diego
Graduated: 1975
Steven Kh Foung, Palo Alto CA
Specialties:
Pediatrician
Address:
3373 Hillview Ave, Palo Alto, CA 94304
Human Neutralizing Monoclonal Antibodies To H5N1 Influenza A Virus
US Patent:
7879326, Feb 1, 2011
Filed:
Jun 16, 2008
Appl. No.:
12/140151
Inventors:
Steven Foung - Stanford CA, US
Richard Webby - Memphis TN, US
Richard Webby - Memphis TN, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
St. Jude Children's Research Hospital - Memphis TN
St. Jude Children's Research Hospital - Memphis TN
International Classification:
A61K 39/42, C07K 16/10, C12N 15/13, C12N 5/24, C12N 5/10
US Classification:
4241421, 4241471, 53038815, 5303883, 536 2352, 435339
Abstract:
A panel of IgGhuman monoclonal antibodies (HMAbs) identified by hemagglutination inhibition (HI) assay has been produced from peripheral B cells of an individual immunized with prototype H5N1 vaccine. Sequence analysis of antibody clones showed three clusters of different HMAbs as represented by HMAbs designated as BF1-1, BF1-19 and BF1-10. BF1-1 and BF1-10 have distinct CDR 1, 2 and 3 regions of both heavy and light chains. BF1-19 has the same heavy chain as BF1-1 but the light chain of BF1-10. Antibody binding affinity, K, studies showed all three HMAbs ranging from at least about 10to at least about 10. In vivo protection studies showed that these antibodies afforded significant protection against infection. These findings demonstrate that the antibodies of the invention are cross-neutralizing and therapeutic.
Prevention And Treatment Of Hcv Infection Employing Antibodies Directed Against Conformational And Linear Epitopes
US Patent:
2003018, Sep 25, 2003
Filed:
Jul 2, 2002
Appl. No.:
10/188608
Inventors:
Steven Foung - Stanford CA, US
Assignee:
Board of Trustees of Leland Stanford Junior University
International Classification:
A61K039/42, C07K016/08, A61K031/00, A01N061/00, A61K039/395, C07K016/00, C12P021/08
US Classification:
424/130100, 514/001000, 424/161100, 530/388300, 424/143100
Abstract:
Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.
Prevention And Treatment Of Hcv Infection Employing Antibodies Directed Against Conformational Epitopes
US Patent:
2006010, May 18, 2006
Filed:
Dec 1, 2000
Appl. No.:
09/728720
Inventors:
Steven Foung - Stanford CA, US
Kenneth Hadlock - San Francisco CA, US
Kenneth Hadlock - San Francisco CA, US
International Classification:
A61K 39/42, C12Q 1/70, C07K 16/08
US Classification:
424149100, 435005000, 530388300
Abstract:
Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.
Prevention And Treatment Of Hcv Infection Employing Antibodies Directed Against Conformational And Linear Epitopes
US Patent:
2006018, Aug 24, 2006
Filed:
Oct 5, 2004
Appl. No.:
10/958624
Inventors:
Steven Foung - Stanford CA, US
Kenneth Hadlock - San Francisco CA, US
Zhenyong Keck - Redwood City CA, US
Kenneth Hadlock - San Francisco CA, US
Zhenyong Keck - Redwood City CA, US
International Classification:
A61K 39/42
US Classification:
424161100
Abstract:
Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen. Pharmaceutical compositions for prevention and treatment of HCV, comprising one or more the monoclonal antibodies, are provided.
Prevention And Treatment Of Hcv Infection Employing Antibodies Directed Against Conformational Epitopes
US Patent:
2007003, Feb 8, 2007
Filed:
Aug 15, 2006
Appl. No.:
11/504974
Inventors:
Steven Foung - Stanford CA, US
Kenneth Hadlock - San Francisco CA, US
Kenneth Hadlock - San Francisco CA, US
International Classification:
C07H 21/04, C07K 14/00, C07K 16/00, A61K 38/00, C07K 17/00, C07K 2/00, C07K 4/00, C07K 5/00, C07K 7/00
US Classification:
530300000, 536023720
Abstract:
Conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conformational epitopes have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.
Method And Assay For Htlv
US Patent:
5643714, Jul 1, 1997
Filed:
Feb 5, 1993
Appl. No.:
8/014153
Inventors:
Kenneth G. Hadlock - Hayward CA
Chin-Joo Goh - Singapore, SG
Steven K.H. Foung - Stanford CA
Chin-Joo Goh - Singapore, SG
Steven K.H. Foung - Stanford CA
Assignee:
Genelabs Technologies, Inc. - Redwood City CA
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
C12Q 170, C12Q 168, G01N 3353, C07K 1415
US Classification:
435 5
Abstract:
Novel HTLV-I and HTLV-II peptides are disclosed for use in diagnostic assays for detecting and confirming HTLV-I and HTLV-II infection in human sera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp21 envelope protein, and are diagnostic of HTLV-I or HTLV-II infection. The invention also includes an assay kit and method for detecting, and discriminating between, HTLV-I and HTLV-II infection in humans.
Hepatitis C Antibodies And Uses Thereof
US Patent:
2012003, Feb 16, 2012
Filed:
Oct 5, 2008
Appl. No.:
13/122598
Inventors:
Steven Foung - Stanford CA, US
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - Palo Alto CA
International Classification:
A61K 38/21, C12N 5/0781, A61P 31/14, C12N 5/071, A61K 39/42, C07K 16/10, C12N 5/16
US Classification:
424 854, 5303894, 53038815, 5303873, 435339, 4241421, 4241611, 5303883
Abstract:
The present invention provides identification and characterization of conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV). The present invention provides a panel of human monoclonal antibodies that recognize conformational epitopes of E2. The antibodies are derived from patients infected with HCV. The present invention provides methods for utilizing HCV antibodies as therapeutic, diagnostic, and/or prophylactic agents. The present invention provides mimotopes with conformational epitopes intact and methods of using mimotopes. The present invention provides methods of stratifying patients based on their response to HCV. The present invention provides pharmaceutical compositions for prevention and treatment of HCV comprising one or more HCV antibodies.